p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity

被引:43
作者
Vaughan, Catherine A. [1 ]
Singh, Shilpa [2 ]
Windle, Brad [2 ,3 ]
Sankala, Heidi M. [4 ]
Graves, Paul R. [2 ,4 ]
Yeudall, W. Andrew [1 ,2 ,5 ]
Deb, Swati P. [1 ,2 ]
Deb, Sumitra [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA
[4] Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA
[5] Virginia Commonwealth Univ, Philips Inst, Richmond, VA 23298 USA
关键词
Mutant p53; Gain of function; Transactivation; NF-KAPPA-B; OF-FUNCTION PHENOTYPE; PROSTATE-CANCER; GENE-EXPRESSION; SQUAMOUS CARCINOGENESIS; TRANSACTIVATION DOMAINS; CHEMICAL CARCINOGENESIS; UP-REGULATION; WILD-TYPE; ACTIVATION;
D O I
10.1016/j.abb.2011.12.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 and show "gain of function" (GOF) phenotypes such as increased growth rate, enhanced resistance to chemotherapeutic drugs, increased cell motility and tumorigenicity; although the mechanism for this function remains unknown. In this communication we report that p53-mediated NF-kappa B2 up-regulation significantly contributes to the aggressive oncogenic behavior of cancer cells. Lowering the level of mutant p53 in a number of cancer cell lines resulted in a loss of GOF phenotypes directly implicating p53 mutants in the process. RNAi against NF-kappa B2 in naturally occurring cancer cell lines also lowers GOF activities. In H1299 cells expressing mutant p53, chromatin immunoprecipitation (ChIP) assays indicate that mutant p53 induces histone acetylation at specific sites on the regulatory regions of its target genes. ChIP assays using antibodies against transcription factors putatively capable of interacting with the NF-kappa B2 promoter show increased interaction of CBP and STAT2 in the presence of mutant p53. Thus, we propose that in H1299 cells, mutant p53 elevates expression of genes capable of enhancing cell proliferation, motility, and tumorigenicity by inducing acetylation of histones via recruitment of CBP and STAT2 on the promoters causing CBP-mediated histone acetylation. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 53 条
[1]  
Albor A, 1998, CANCER RES, V58, P2091
[2]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[3]   p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1 [J].
Bohuslav, J ;
Chen, LF ;
Kwon, H ;
Mu, YJ ;
Greene, WC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (25) :26115-26125
[4]   Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53 [J].
Bristow, RG ;
Peacock, J ;
Jang, A ;
Kim, J ;
Hill, RP ;
Benchimol, S .
ONCOGENE, 2003, 22 (19) :2960-2966
[5]   The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J].
Cadwell, C ;
Zambetti, GP .
GENE, 2001, 277 (1-2) :15-30
[6]   Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer [J].
Catz, SD ;
Johnson, JL .
ONCOGENE, 2001, 20 (50) :7342-7351
[7]   MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53 [J].
CHIN, KV ;
UEDA, K ;
PASTAN, I ;
GOTTESMAN, MM .
SCIENCE, 1992, 255 (5043) :459-462
[8]  
Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035
[9]   MODULATION OF CELLULAR AND VIRAL PROMOTERS BY MUTANT HUMAN P53-PROTEINS FOUND IN TUMOR-CELLS [J].
DEB, S ;
JACKSON, CT ;
SUBLER, MA ;
MARTIN, DW .
JOURNAL OF VIROLOGY, 1992, 66 (10) :6164-6170
[10]   Function and dysfunction of the human oncoprotein MDM2 [J].
Deb, SP .
FRONTIERS IN BIOSCIENCE, 2002, 7 :D235-D243